NCT04795882|RecruitingPhase 1DMC
A New Study Evaluating the Activity of Modular CAR T for mYeloma
MCARTY
An Open Label, Phase 1 Study Evaluating the Activity of Modular CAR T for mYeloma
Loading search results
Sponsor study identifier
interventional
27
1 country
1
Study Start
April 22, 2022
Actual (reported)Primary Completion
March 31, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
March 31, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This is a Phase 1 rolling 6 trial design evaluating safety of a novel BCMA Chimeric Antigen Receptor (CAR) alone and of CAR T cells engineered to co-express BCMA CAR and a CD19 CAR in patients with relapsed / refractory Multiple Myeloma. The study will assess the feasibility of generating these Advanced Therapy Investigational Products (ATIMPs) and the safety of administering the CAR T cells (either BCMA alone or co-expressed with CD19) in patients with relapsed / refractory multiple myeloma.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 31, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2, 2021
Actual (reported)March 12, 2021
Actual (reported)April 22, 2022
Actual (reported)March 31, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
March 31, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Toxicity evaluated by the incidence of grade 3-5 toxicity causally related to the Advanced Therapy Investigational Product (ATIMP)
The incidence of grade 3-5 toxicity assessed using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 and the American Society for Transplantation and Cellular Therapy (ASTCT) Cytokine Release Syndrome (CRS) and Neurotoxicity tool
28 days
Feasibility of manufacturing CAR T-cells evaluated by the number of therapeutic products generated
Feasibility of generation of CAR T cells as evaluated by the number of therapeutic products generated.
30 days
Treatment with Advanced Therapy Investigational Product (ATIMP): BCMA CAR T-cells
Treatment with Advanced Therapy Investigational Product (ATIMP): BCMA/CD19 CAR T-cells
Infusion with ATIMP: BCMA CAR T-cells
Infusion with ATIMP: BCMA/CD19 CAR T-cells
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
University College London Hospital
London, County (Optional), United Kingdom
Lydia Lee
CONTACT
First Submitted
March 2, 2021
First Posted
March 12, 2021
Study Start
April 22, 2022
Actual (reported)Primary Completion
March 31, 2029
EstimatedP-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
March 31, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
November 20, 2025
Record last verified: 2025-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: